Lupus

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smolen, J S
Right arrow Articles by Aringer, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smolen, J S
Right arrow Articles by Aringer, M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Lupus, Vol. 14, No. 3, 189-191 (2005)
DOI: 10.1191/0961203305lu2134oa

Anti-cytokine therapy in systemic lupus erythematosus

J S Smolen

Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

G Steiner

Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

M Aringer

Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

In the course of the disease, a wide variety of cytokines is dysregulated, many of which likely influence systemic lupus erythematosus (SLE) autoimmunity and/or lupus tissue inflammation. Proinflammatory cytokines in particular, such as TNF, IL-6, IL-18 or IFN-gamma, may play a major role in propagating the inflammatory processes responsible for tissue damage. These cytokines are overexpressed both systemically and locally, and preliminary results from open-label trials and/or animal studies suggest potential benefits of blocking either of these inflammatory mediators. Since new therapeutic agents may soon offer many ways to influence the process, controlled clinical trials following open-label safety studies are of central importance to arrive at optimized therapies for SLE patients.

Key Words: infliximab • interferon-gamma • interleukins • nephritis • tumour necrosis factor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
E. MacDermott, A. Adams, and T. Lehman
Review: Systemic lupus erythematosus in children: current and emerging therapies
Lupus, August 1, 2007; 16(8): 677 - 683.
[Abstract] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
P. C Calder
n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases
Am. J. Clinical Nutrition, June 1, 2006; 83(6): S1505 - 1519S.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
A Wozniacka, A Lesiak, J Narbutt, D P McCauliffe, and A Sysa-Jedrzejowska
Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients
Lupus, May 1, 2006; 15(5): 268 - 275.
[Abstract] [PDF]

Home page
 J. Immunol.Home page
G. Rai, S. Ray, R. E. Shaw, P. F. DeGrange, R. G. Mage, and B. A. Newman
Models of Systemic Lupus Erythematosus: Development of Autoimmunity Following Peptide Immunizations of Noninbred Pedigreed Rabbits
J. Immunol., January 1, 2006; 176(1): 660 - 667.
[Abstract] [Full Text] [PDF]